Thrombotic Thrombocytopenic Purpura, Heparin-Induced Thrombocytopenia, and Disseminated Intravascular Coagulation
- PMID: 32172818
- DOI: 10.1016/j.ccc.2019.12.006
Thrombotic Thrombocytopenic Purpura, Heparin-Induced Thrombocytopenia, and Disseminated Intravascular Coagulation
Abstract
Hemostatic abnormalities are common among critically ill patients and are associated with a high risk of bleeding. The abnormalities range from isolated thrombocytopenia or prolongation of global coagulation assays to complex disease states, such as thrombotic microangiopathic syndromes, and can be associated with a wide range of conditions, including trauma, surgery, acute disease processes, cardiopulmonary bypass, and exposure to drugs and blood products. Prompt identification of underlying causes is important because treatment strategies vary. Moreover, prompt initiation of both supportive and specific treatments is vital to decrease the morbidity and mortality in the intensive care unit.
Keywords: Caplacizumab; Heparin; ICU; Microangiopathic hemolytic anemia; Plasmapheresis; Rituximab; Thrombocytopenia; Thrombotic microangiopathy.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure R. Kalpatthi has nothing to disclose. J.E. Kiss reports service as a paid consultant on the medical advisory board for Sanofi, the maker of caplacizumab.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
